This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Master Pharm Future Growth

Future criteria checks 0/6

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Personal Products earnings growth7.6%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Calculating The Intrinsic Value Of Master Pharm SA (WSE:MPH)

Feb 05
Calculating The Intrinsic Value Of Master Pharm SA (WSE:MPH)

Returns On Capital At Master Pharm (WSE:MPH) Have Hit The Brakes

Dec 13
Returns On Capital At Master Pharm (WSE:MPH) Have Hit The Brakes

A Look At The Intrinsic Value Of Master Pharm SA (WSE:MPH)

May 25
A Look At The Intrinsic Value Of Master Pharm SA (WSE:MPH)

Master Pharm (WSE:MPH) Will Will Want To Turn Around Its Return Trends

Mar 30
Master Pharm (WSE:MPH) Will Will Want To Turn Around Its Return Trends

Is Master Pharm SA's (WSE:MPH) Latest Stock Performance Being Led By Its Strong Fundamentals?

Mar 02
Is Master Pharm SA's (WSE:MPH) Latest Stock Performance Being Led By Its Strong Fundamentals?

I Ran A Stock Scan For Earnings Growth And Master Pharm (WSE:MPH) Passed With Ease

Feb 04
I Ran A Stock Scan For Earnings Growth And Master Pharm (WSE:MPH) Passed With Ease

Master Pharm (WSE:MPH) Is Growing Earnings But Are They A Good Guide?

Jan 08
Master Pharm (WSE:MPH) Is Growing Earnings But Are They A Good Guide?

Here's What To Make Of Master Pharm's (WSE:MPH) Returns On Capital

Dec 18
Here's What To Make Of Master Pharm's (WSE:MPH) Returns On Capital

Master Pharm SA (WSE:MPH) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

Nov 27
Master Pharm SA (WSE:MPH) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Master Pharm has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

WSE:MPH - Analysts future estimates and past financials data (PLN Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/20227921517N/A
3/31/20227341717N/A
12/31/20217741013N/A
9/30/202172-31014N/A
6/30/202175246N/A
3/31/202169168N/A
12/31/20206101315N/A
9/30/202063121517N/A
6/30/202068131516N/A
3/31/202071121213N/A
12/31/2019711367N/A
9/30/2019739910N/A
6/30/201974989N/A
3/31/2019729910N/A
12/31/201875111314N/A
9/30/2018751135N/A
6/30/2018701046N/A
3/31/201868914N/A
12/31/2017648-6-3N/A
9/30/2017577-41N/A
6/30/2017526-42N/A
3/31/2017518-16N/A
12/31/2016497-15N/A
9/30/201650835N/A
6/30/201653745N/A
3/31/2016539N/A1N/A
12/31/2015498N/A3N/A
9/30/2015438N/A4N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if MPH's forecast earnings growth is above the savings rate (2.6%).

Earnings vs Market: Insufficient data to determine if MPH's earnings are forecast to grow faster than the Polish market

High Growth Earnings: Insufficient data to determine if MPH's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if MPH's revenue is forecast to grow faster than the Polish market.

High Growth Revenue: Insufficient data to determine if MPH's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if MPH's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.